EVOGENE WKN: A0Q7UP ISIN: IL0011050551 Kürzel: E3V Forum: Aktien Thema: Hauptdiskussion

https://www.prnewswire.com/il/news-releases/evogene-reports-fourth-quarter-and-full-year-2021-financial-results-301499893.html

🎈

Evogene Reports Third Quarter 2021 Financial Results https://www.prnewswire.com/news-releases/evogene-reports-third-quarter-2021-financial-results-301426621.html

Evogene Announces Participation in the Second Research Period of the CRISPR-IL Consortium https://www.prnewswire.com/news-releases/evogene-announces-participation-in-the-second-research-period-of-the-crispr-il-consortium-301420838.html Israeli Innovation Authority to continue funding the on-going development of an end-to-end artificial intelligence system for genome-editing

Lavie Bio Announces Commercial Launch of its First Microbiome-Based Product for Yield Improvement - result™ https://www.prnewswire.com/news-releases/lavie-bio-announces-commercial-launch-of-its-first-microbiome-based-product-for-yield-improvement---result-301415083.html

Evogene subsidiary Biomica signs pact for cancer trial on microbiome-based asset https://seekingalpha.com/news/3758941-evogene-subsidiary-biomica-signs-pact-for-cancer-trial-on-microbiome-based-asset Biomica, a subsidiary of Evogene (NASDAQ:EVGN), has formed a clinical trial agreement (CTA) with the Israeli healthcare institution, Rambam Health Care Campus, to start the first-in-human  proof-of-concept study for BMC128. In the Phase 1 study, the microbiome-based immuno-oncology drug candidate developed by Biomica will be evaluated for safety and tolerability in combination with anti-PD-1 in patients with Non-small Cell Lung Cancer (NSCLC), Melanoma, or Renal Cell Carcinoma (RCC). The beginning of the trial is subject to clearance from the Israeli Ministry of Health ((MoH)). “Based on the compelling preclinical results achieved to-date, we are thrilled to take this next step in advancing BMC128 through the clinical development process,” CEO of Biomica Elran Haber noted. In April, the company disclosed pre-clinical results for BMC128 in melanoma, causing Evogene (EVGN) shares to gain in the pre-market.

Evogene : Canonic moves ahead of schedule with the full commercial launch of its G-nnovation products, following positive feedback from patients during the company's pre-launch campaign - Form 6-K https://www.marketscreener.com/quote/stock/EVOGENE-LTD-120962472/news/Evogene-Canonic-moves-ahead-of-schedule-with-the-full-commercial-launch-of-its-G-nnovation-product-36715825/

https://www.marketscreener.com/quote/stock/EVOGENE-LTD-120962472/news/Evogene-Lavie-Bio-and-United-Agronomy-Announce-Signing-of-Distribution-Agreement-for-Lavie-Bio-s-I-36548784/

Evogene : Canonic Announces Pre-Launch of its First Generation Medical Cannabis Products in Israel https://www.marketscreener.com/quote/stock/EVOGENE-LTD-120962472/news/Evogene-Canonic-Announces-Pre-Launch-of-its-First-Generation-Medical-Cannabis-Products-in-Israel-36288842/ Pre-launch of G-nnovation product line to a limited number of patients; Full commercial launch expected in 2022

Evogene Reports Second Quarter 2021 Financial Results https://finance.yahoo.com/news/evogene-reports-second-quarter-2021-110000165.html https://www.earningswhispers.com/epsdetails/evgn Evogene Ltd Ord (EVGN) reported a 2nd Quarter June 2021 loss of $0.15 per share on revenue of $0.1 million. on revenue of $0.3 million. Revenue fell 54.7% compared to the same quarter a year ago.

Evogene : AgPlenus Announces Positive Results for a Herbicide Resistance Trait to its Leading Herbicide Product Candidate https://www.marketscreener.com/quote/stock/EVOGENE-LTD-56536833/news/Evogene-nbsp-AgPlenus-Announces-Positive-Results-for-a-Herbicide-Resistance-Trait-to-its-Leading-H-35797014/

Evogene Reports First Quarter 2021 Financial Results https://www.marketscreener.com/quote/stock/CORTEVA-INC-59241389/news/Corteva-nbsp-Evogene-Reports-First-Quarter-2021-Financial-Results-Evogene-33357979/ Evogene Q1 EPS $(0.17) Up From $(0.24) YoY, Sales $333.00K Beat $300.00K Estimate https://www.benzinga.com/news/earnings/21/05/21294854/evogene-q1-eps-0-17-up-from-0-24-yoy-sales-333-00k-beat-300-00k-estimate Evogene (NASDAQ:EVGN) reported quarterly losses of $(0.17) per share. This is a 29.17 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $333.00 thousand which beat the analyst consensus estimate of $300.00 thousand by 11.00 percent. This is a 344.00 percent increase over sales of $75.00 thousand the same period last year.

Biomica Announces Positive Pre-Clinical Results, Demonstrating Efficacy of BMC128 in Melanoma https://www.prnewswire.com/news-releases/biomica-announces-positive-pre-clinical-results-demonstrating-efficacy-of-bmc128-in-melanoma-301267404.html Biomica's live biotherapeutic drug candidate, BMC128, significantly increased anti-tumor activity in combination with Immune Checkpoint Inhibitors in Melanoma. First-in-human, proof of concept study expected later this year

Plastomics and Evogene's Ag-Seed division enter a collaborative agreement targeting novel insect control traits for soybean https://www.prnewswire.com/il/news-releases/plastomics-and-evogenes-ag-seed-division-enter-a-collaborative-agreement-targeting-novel-insect-control-traits-for-soybean-301249298.html The parties will test in soybean, Evogene's candidate genes for insect control utilizing Plastomics' novel chloroplast transformation technology  ...

Heftig, wie der Wert hier zerissen wird seit Tagen. Mehr als 50% gefallen. Komplette Übertreibung. Gut gelaufen hin oder her...